Fluent BioSciences
Biotechnology company developing accessible single-cell sequencing technology using PIPseq (Particle-templated Instant Partitions), enabling high-throughput single-cell analysis without specialized equipment.
Notes
Fluent BioSciences is a biotechnology company making single-cell sequencing more accessible and affordable through its innovative PIPseq technology. Unlike competing approaches that require expensive microfluidics equipment, PIPseq uses pre-templated particles that work in standard laboratory tubes, dramatically lowering the barrier to entry for single-cell research.
The company emerged from Harvard's Weitz lab and was founded to democratize single-cell genomics. Their technology allows researchers to analyze millions of cells without specialized instruments, making it particularly valuable for large-scale studies and laboratories with limited equipment budgets.
Fluent BioSciences offers kits for single-cell RNA sequencing, ATAC-seq, and multiomics applications. The company has partnerships with major research institutions and has been adopted by academic and pharmaceutical researchers worldwide.
Team
- Ravi Sheth, Ph.D. - Co-founder & CEO
- LinkedIn: linkedin.com/in/ravisheth
- David Weitz, Ph.D. - Scientific Co-founder (Harvard Professor)
- Adam Sciambi, Ph.D. - Chief Technology Officer
Additional Research Findings
- Founded in 2019, spun out from Harvard's Weitz lab
- PIPseq technology enables equipment-free single-cell sequencing
- No microfluidics required - works in standard lab tubes
- Raised $45 million Series A in 2021 led by Northpond Ventures
- Key investors include Northpond Ventures, Novo Holdings, and Alexandria Venture Investments
- Competes with 10x Genomics, Parse Biosciences, and Scale Biosciences
- Products include single-cell RNA-seq, ATAC-seq, and multiome kits
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Illumina Ventures | San Francisco, California, USA | biotech-focused | seedseries-a+1 | 32 |